Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCEPTATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Correction of hypokalemia,Prevention of hypokalemia in patients receiving potassium-depleting therapies,Intravenous source of calories (dextrose component)
Treatment of hypocalcemia,Calcium supplementation in patients requiring parenteral calcium,Treatment of hypermagnesemia,Cardiac resuscitation (as an adjunct),Treatment of calcium channel blocker overdose
Intravenous infusion; typical adult dose: 10-20 m Eq per hour, not exceeding 40 m Eq per dose and 200 m Eq per day, titrated based on serum potassium and ECG monitoring.
IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism.
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle.
Calcium gluceptate is not metabolized; it dissociates into calcium ions and gluceptate. Calcium ions are excreted primarily in feces and urine, with renal handling involving reabsorption and secretion.
Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion.
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
Potassium is not significantly protein-bound (<10%). Dextrose has negligible protein binding. No specific binding proteins identified for potassium; it exists as free ion in plasma.
~45% bound to albumin.
Potassium Vd is approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid. Total body potassium is ~50 m Eq/kg, with 98% intracellular. The clinical meaning: initial dose distributes into ECF before equilibrating with ICF; rapid IV administration can cause transient hyperkalemia.
0.15-0.25 L/kg; represents distribution mainly in extracellular fluid.
Intravenous administration yields 100% bioavailability. Oral potassium chloride has ~90-100% bioavailability, but this formulation is not for oral use. Dextrose only given IV; not applicable for oral.
IV: 100%; IM: not well characterized; oral: negligible (absorbed poorly, systemic bioavailability <1% as calcium gluceptate dissociates in GI tract).
For GFR 30-50 m L/min: reduce infusion rate by 25%; GFR 15-29: reduce rate by 50%; GFR <15: avoid use or use with extreme caution at reduced rate, monitor potassium closely.
GFR >50: No adjustment. GFR 30-50: Reduce dose by 25%. GFR <30: Reduce dose by 50% and monitor serum calcium closely. Dialysis: Dose after hemodialysis.
No specific Child-Pugh based adjustments; monitor serum potassium and acid-base status closely in hepatic impairment due to risk of hyperkalemia.
No dose adjustment required for hepatic impairment. However, monitor ionized calcium in severe hepatic failure due to altered binding proteins.
Intravenous infusion; 0.5-1 m Eq/kg per dose, maximum 40 m Eq per dose, infused at rate not exceeding 0.5-1 m Eq/kg/hour; adjust based on serum potassium and clinical response.
Neonates and infants: 100-200 mg elemental calcium/kg/day IV divided every 6 hours. Children: 200-500 mg elemental calcium/kg/day IV divided every 6 hours. Maximum: 1 g elemental calcium per dose.
Use lower initial infusion rates (e.g., 5-10 m Eq/hour) due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion.
Use lower initial doses (e.g., 1-2 mg/kg elemental calcium) due to reduced renal function and increased risk of hypercalcemia. Monitor serum calcium and phosphate levels.
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can lead to cardiac arrest.
No FDA black box warning.
Risk of hyperkalemia, especially in patients with renal impairment,Cardiac monitoring recommended during infusion,Avoid rapid intravenous administration,Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders,May cause phlebitis at injection site
Risk of hypercalcemia, especially in patients with renal impairment,Avoid rapid intravenous administration to prevent cardiac arrest,Use with caution in patients with sarcoidosis or digitalis toxicity,Monitor serum calcium levels during therapy,Extravasation may cause tissue necrosis
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal failure with oliguria or azotemia,Concurrent use of potassium-sparing diuretics (unless under close monitoring),Acidosis (may worsen hyperkalemia),Crush injury or massive hemolysis (risk of acute hyperkalemia),Addison's disease (untreated)
Hypercalcemia,Hypersensitivity to calcium gluceptate or any component,Ventricular fibrillation,Patients with known calcium-containing calculi
No specific food interactions with IV potassium chloride and dextrose. However, while on treatment, avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by your doctor, as concurrent dietary potassium may increase risk of hyperkalemia.
Avoid high-calcium foods (dairy, fortified cereals) during acute therapy to prevent hypercalcemia. Limit vitamin D-rich foods (fatty fish, fortified milk). Do not take oral calcium within 1 hour of iron or thyroid medications. Avoid excessive caffeine and alcohol.
No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No increased risk of congenital anomalies reported. However, maternal hyperkalemia or severe hypoglycemia may indirectly affect fetal well-being.
Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No increased risk of major malformations. Second and third trimesters: Adequate intake supports fetal skeletal mineralization; excess may cause hypercalcemia in the infant. No known teratogenicity.
Potassium chloride and dextrose are normal constituents of breast milk. Supplementation does not significantly alter milk composition. No adverse effects in nursing infants expected. M/P ratio not applicable as substances are endogenous.
Calcium gluceptate is considered safe during breastfeeding. Calcium is naturally present in breast milk; supplementation does not significantly alter milk calcium levels. M/P ratio not established, but endogenous calcium transport suggests minimal risk. Use with caution in mothers with hypercalcemia.
No specific dose adjustments required due to pregnancy. Monitor for fluid overload in preeclampsia or compromised cardiac function. Glucose-containing solutions necessitate glucose monitoring in diabetes. Potassium supplementation should be guided by serum potassium levels.
No specific dose adjustment required in pregnancy; maintain recommended daily intake (1000-1300 mg elemental calcium). Pharmacokinetic changes in pregnancy (increased absorption, renal clearance) may slightly alter requirements, but standard doses are safe. Intravenous use should be adjusted based on serum calcium monitoring.
Potassium chloride 0.3% in dextrose 5% provides 40 m Eq/L of potassium and 50 g/L of dextrose. Administer via peripheral line; central line preferred for concentrations >40 m Eq/L. Never give IV push. Infusion rate should not exceed 10 m Eq/h or 200 m Eq/24h without cardiac monitoring. Contraindicated in severe hyperkalemia, renal failure with oliguria, and untreated Addison's disease. Use with caution in patients with cardiac disease, digoxin therapy, or metabolic acidosis. Monitor serum potassium and ECG continuously during infusion.
Calcium gluceptate is used for acute hypocalcemia, hyperkalemia cardiotoxicity, and hypermagnesemia. Administer IV slowly (0.5-1 m L/min) to avoid arrhythmias; monitor ECG during infusion. Do not mix with bicarbonate, phosphate, or sulfate-containing solutions. Extravasation causes tissue necrosis; use central line for peripheral therapy. Correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia.
This medication is given through a vein to correct low potassium levels.,Report any pain, redness, or swelling at the IV site immediately.,You may experience increased thirst or urination due to the dextrose content.,Do not stop treatment abruptly without consulting your healthcare provider.,Inform your doctor of all medications you take, especially digoxin and diuretics.
Report any burning or pain at injection site immediately.,Avoid taking calcium supplements or antacids without consulting your doctor.,Tell your doctor if you have kidney stones, parathyroid disorders, or heart disease.,Do not stop other calcium medications abruptly.,Seek emergency care for difficulty breathing or chest tightness after infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCEPTATE, answered by our medical review team.
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.. CALCIUM GLUCEPTATE is a Electrolyte Supplement that works by Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCEPTATE depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose: 10-20 m Eq per hour, not exceeding 40 m Eq per dose and 200 m Eq per day, titrated based on serum potassium and ECG monitoring.. The standard adult dose of CALCIUM GLUCEPTATE is: IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCEPTATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No . CALCIUM GLUCEPTATE is classified as Category C. Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.